Huntingtin and its role in neuronal degeneration

Neuroscientist

Volumn 10, Issue 5, 2004, Pages 467-475

  Li, Shi Hua ^a   Li, Xiao Jiang ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggregation; Huntington; Neurodegeneration; Pathogenesis; Polyglutamine

Indexed keywords

HUNTINGTIN; POLYGLUTAMINE;

AMINO TERMINAL SEQUENCE; APOPTOSIS; BODY MASS; BRAIN; BRAIN DYSFUNCTION; BRAIN REGION; CYTOTOXICITY; DEMENTIA; DISEASE COURSE; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; IMMUNOREACTIVITY; INTRACELLULAR TRANSPORT; NERVE CELL; NERVE CELL DEGENERATION; NERVE FIBER DEGENERATION; NERVE FIBER TRANSPORT; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPIL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSYCHIATRY; REVIEW; TOXICITY;

ANIMALS; HUMANS; HUNTINGTON DISEASE; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS;

EID: 4544293517     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/1073858404266777     Document Type: Review

References (69)

1. Albin RL, Young AB, Penney JB, Handelin B, Balfour R, Anderson KD, and others. 1990. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 322:1293-8.
2. Albin RL, Reiner A, Anderson KD, Dure LS IV, Handelin B, Balfour R, and others. 1992. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 31:425-30.
3. Beal MF 1994. Huntington's disease, energy, and excitotoxicity. Neurobiol Aging 15:275-6.
4. Bence NF, Sampat RM, Kopito RR. 2001. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292:1552-5.
5. Block-Galarza J, Chase KO, Sapp E, Vaughn KT, Vallee RB, DiFiglia M, and others. 1997. Fast transport and retrograde movement of huntingtin and HAP 1 in axons. Neuroreport 8:2247-51.
6. Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S. 2001. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 24:182-8.
7. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, and others. 1998. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A 95:6480-5.
8. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, and others. 2000. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801.
9. Coleman MP, Perry VH 2002. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 25:532-7.
10. Coyle JT, Schwarcz R. 1976. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263:244-6.
11. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, and others. 1997. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-48.
12. DiFiglia M. 1990. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 13:286-9.
13. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, and others. 1997. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuntes in brain. Science 277:1990-3.
14. Dragatsis I, Levine MS, Zeitlin S. 2000. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26:300-6.
15. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, and others. 2002. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296:2238-43.
16. Ferrante RJ, Kowall NW, Beal MF, Richardson EP Jr, Bird ED, Martin JB. 1985. Selective sparing of a class of striatal neurons in Huntington's disease. Science 230:561-3.
17. Gines S, Ivanova E, Seong IS, Saura CA, MacDonald ME. 2003. Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J Biol Chem 278:50514-22.
18. Graveland GA, Williams RS, DiFiglia M. 1985. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227:770-3.
19. Guidetti P, Charles V, Chen EY, Reddy PH, Kordower JH, Whetsell WO Jr, and others. 2001. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol 169:340-50.
20. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, Gordesky-Gold B, and others. 2003. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40:25-40.
21. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, and others. 1999. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19:2522-34.
22. Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-83.
23. Harjes P, Wanker EE. 2003. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 28:425-33.
24. Harper PS. 1991. Huntington's disease. Philadelphia: W. B. Saunders.
25. Hedreen JC, Peyser CE, Folstein SE, Ross CA. 1991. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett 133:257-61.
26. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, and others. 1999. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181-92.
27. Kita H, Carmichael J, Swartz J, Muro S, Wyttenbach A, Matsubara K, and others. 2002. Modulation of polyglutamine-induced cell death by genes identified by expression profiling. Hum Mol Genet 11:2279-87.
28. Kremer HP, Roos RA, Dingjan G, Marani E, Bots GT. 1990. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol 49:371-82.
29. Lee WC, Yoshihara M, Littleton JT. 2004. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci U S A 101:3224-9.
30. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, and others. 1999. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58:515-32.
31. Li SH, Cheng AL, Zhou H, Lam S, Rao M, Li H, Li XJ. 2002. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22:1277-87.
32. Li SH, Lam S, Cheng AL, Li XJ. 2000. Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. Hum Mol Genet 9:2859-67.
33. Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, Li XJ. 1999. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet 8:1227-36.
34. Li H, Li SH, Yu ZX, Shelbourne P, Li XJ. 2001. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci 21:8473-81.
35. Li H, Wyman T, Yu ZX, Li SH, Li XJ. 2003. Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum Mol Genet 12:2021-30.
36. Li SH, Li XJ. 2004. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20:146-54.
37. Li SH, Yu ZX, Li CL, Nguyen HP, Zhou YX, Deng C, Li XJ. 2003. Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease. J Neurosci 23:6956-64.
38. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Grouse AB, and others. 2001. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 10:137-44.
39. Liu YF, Deth RC, Devys D. 1997. SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complexes. J Biol Chem 272:8121-4.
40. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, and others. 2002. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 11:1911-26.
41. McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J, and others. 2000. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9:2197-202.
42. Myers RH, Vonsattel JP, Paskevich PA, Kiely DK, Stevens TJ, Cupples LA, and others. 1991. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol 50:729-42.
43. Nucifora FC Jr, Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M, and others. 2001. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291:2423-8.
44. Obrietan K, Hoyt KR. 2004. CRE-mediated transcription is increased in Huntington's disease transgenic mice. J Neurosci 24:791-6.
45. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, and others. 1999. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399:263-7.
46. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, and others. 2002. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5:731-6.
47. Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, Neri C. 2001. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc Natl Acad Sci U S A 98:13318-23.
48. Raff MC, Whitmore AV, Finn JT. 2002. Axonal self-destruction and neurodegeneration. Science 296:868-71.
49. Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO Jr, and others. 1998. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 20:198-202.
50. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. 1988. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 85:5733-7.
51. Richfield EK, Maguire-Zeiss KA, Vonkeman HE, Voorn P. 1995. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann Neurol 38:852-61.
52. Sanchez I, Mahlke C, Yuan J. 2003. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421:373-9.
53. Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J. 1999. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22:623-33.
54. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, and others. 2001. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60:161-72.
55. Sapp E, Penney J, Young A, Aronin N, Vonsattel JP, DiFiglia M. 1999. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol 58:165-73.
56. Saudou F, Finkbeiner S, Devys D, Greenberg ME. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66.
57. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, and others. 1999. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8:397-407.
58. Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, Pritchard J, and others. 2002. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 11:1953-65.
59. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, and others. 2001. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-43.
60. Szebenyi G, Morfini GA, Babcock A, Gould M, Selkoe K, Stenoien DL, and others. 2003. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40:41-52.
61. Usdin MT, Shelbourne PF, Myers RM, Madison DV 1999. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum Mol Genet 8:839-46.
62. Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL. 2004. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 14:95-104.
63. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. 1985. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-77.
64. Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, and others. 2000. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9:503-13.
65. Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ. 2003. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci 23:2193-202.
66. Yu ZX, Li SH, Nguyen HP, Li XJ. 2002. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum Mol Genet 11:905-14.
67. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, and others. 2002. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33:849-60.
68. Zhou H, Cao F, Wang Z, Yu ZX, Nguyen HP, Evans J, and others. 2003. Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol 163:109-18.
69. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, and others. 2003. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35:76-83.